Actos and Bladder Cancer- An Overview
Actos (Pioglitazone) is a drug that helps patients with type II diabetes control their blood sugar levels. It has been associated with problems such as weight gain and congestive heart failure and has been linked to an increased risk of bladder cancer in certain patients.
Bladder Cancer Studies and Warnings
- March 2011– The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) started a European review of pioglitazone-containing medicines to investigate a possible increased risk of bladder cancer with pioglitazone.
- June 2011– The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.
- September 2011– The French Medicines Agency announced it was suspending use of the drug until the European Medicines Agency reviewed the risks and benefits.
- June 2012- A Canadian study, published in the British Medical Journal found that taking the diabetes drug Actos for two years can double a person's risk of developing bladder cancer.
Factors Found to Increase Actos Bladder Cancer Risk
- Predisposition to bladder cancer.
- Taking doses higher than 28000 mg.
- Using pioglitazone for more than 2 years.
Contact an Experienced Actos Attorney
Thomas J. Henry are leaders in the area of product liability litigation. Our Defective Drug and Products Division has extensive knowledge and resources in order to represent our clients efficiently and aggressively. We represent a multitude of people who are battling against manufacturers of food, medical devices and defective pharmaceuticals.
Your choice does matter. If you or a loved one has suffered serious injuries including bladder cancer because of Actos, call the Thomas J. Henry immediately. We are available 24/7, nights and weekends.